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Regulated tissue-specific expression of
antagonistic pre-mRNA splicing factors
AKEMI HANAMURA, JAVIER F. CÁCERES,1 AKILA MAYEDA,
B. ROBERT FRANZA JR., and ADRIAN R. KRAINER
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724-2208, USA
ABSTRACT
The SR proteins are essential metazoan pre-mRNA splicing factors that can also influence the selection of alternative
59 splice sites in a concentration-dependent manner. Their activity in alternative splicing in vitro is antagonized by
members of the hnRNP A/B family of proteins. The opposite effects of members of these two families of antagonistic
splicing factors in vitro and upon overexpression in vivo suggest that changes in their relative levels may be a natural
mechanism for the regulation of alternative splicing in vivo. One prediction of this model is that the ratios of these
antagonists should vary in different cell types and in other situations in which cellular or viral transcripts are
differentially spliced. We raised monoclonal antibodies specific for SF2/ASF and used them to measure the abun-
dance of SF2/ASF protein and its isoforms, its phosphorylation state in vivo and during splicing in vitro, and its
association with the spliceosome. SF2/ASF exists predominantly or exclusively in a highly phosphorylated state in
vivo in all cell types examined, and unphosphorylated protein was not detectable. Unphosphorylated recombinant
SF2/ASF becomes rapidly phosphorylated under splicing conditions in HeLa cell extracts and associates stably with
one or more exons of b-globin pre-mRNA. This interaction appears to persist through the splicing reaction and
SF2/ASF remains bound to spliced mRNA. We compared the distribution of SF2/ASF to that of its antagonist, hnRNP
A1, in different rat tissues and in immortal and transformed cell lines. We found that the protein levels of these
antagonistic splicing factors vary naturally over a very wide range, supporting the notion that changes in the ratio of
these proteins can affect alternative splicing of a variety of pre-mRNAs in vivo.
Keywords: hnRNP A1; monoclonal antibodies; phosphorylation; pre-mRNA splicing factors; SF2/ASF; SR proteins
INTRODUCTION
Alternative splicing is a major mechanism for control-
ling the expression of cellular and viral genes, and its
regulation is probably accomplished by subtle varia-
tions of the general splicing mechanism+ Consistent
with this notion, certain components of the general splic-
ing machinery, such as the SR proteins, can affect al-
ternative splice-site selection in a dose-dependent
manner (for reviews see Fu, 1995; Valcarcel & Green,
1996; Cáceres & Krainer, 1997)+ SF2/ASF and other
members of the SR protein family regulate alternative
splicing with a variety of pre-mRNAs, usually by pro-
moting the use of proximal 59 splice sites+ This activity
of SR proteins is counteracted by hnRNP A1 and re-
lated proteins, which generally favor the use of distal 59
splice sites (Mayeda & Krainer, 1992; Mayeda et al+,
1994)+ Therefore, the antagonistic activities of SR pro-
teins and hnRNP A1-like proteins are important deter-
minants of alternative 59 splice-site selection in vitro
and in transfected cells (Cáceres et al+, 1994; Yang
et al+, 1994)+ These experimental observations suggest
that these two families of RNA-binding proteins play
prominent roles in the regulation of alternative splicing
of a wide variety of transcripts in vivo, although the
identity and number of these natural targets remain
unknown+ This hypothetical mechanism of alternative
splicing regulation requires that the relative abundances
or activities of these antagonistic factors vary under
conditions in which one or more transcripts undergo
differential splicing, e+g+, in different cell types or during
development+
All SR proteins are phosphorylated in vivo, as shown,
e+g+, by the fact that a monoclonal antibody, mAb104,
which recognizes a shared phosphoepitope within their
C-terminal RS domains, reacts with all the family mem-
bers (Roth et al+, 1991)+ However, because mAb104
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recognizes the SR proteins only when they are highly
phosphorylated, analyses with this antibody do not re-
veal the extent of their phosphorylation in vivo or the
overall abundance of all the forms of these proteins+ It
is presently unclear whether phosphorylated and/or par-
tially or fully dephosphorylated RS domains are the
active form of this domain in SR proteins+ A role for
reversible protein phosphorylation in the regulation of
both constitutive and alternative splicing has been pos-
tulated (Mermoud et al+, 1992, 1994), and it has also
been shown that changing the levels of active PP1
phosphatase in nuclear extracts results in changes in
alternative 59 splice-site selection (Cardinali et al+, 1994)+
Several protein kinases capable of phosphorylating SR
proteins on serine residues in vitro have been de-
scribed, of which the best characterized are SRPK1
(Gui et al+, 1994a, 1994b) and Clk/Sty (Colwill et al+,
1996a, 1996b)+ Recent experiments showed that, at
least under certain in vitro conditions, both phosphor-
ylation and dephosphorylation cycles may be impor-
tant for constitutive splicing (Cao et al+, 1997; Xiao &
Manley, 1997)+ It has also been proposed that the state
of phosphorylation may control the subnuclear distri-
bution of SR proteins in interphase cells and the reor-
ganization of nuclear speckles during mitosis (Gui
et al+, 1994a; Colwill et al+, 1996b; Misteli & Spector,
1997)+
The observed regulation of alternative splicing by
SF2/ASF and hnRNP A1 levels, both in vitro and in
transfected cells, suggests that changes in the intra-
cellular ratio of these proteins may be sufficient to cause
differential regulation of certain alternative splicing
events in a tissue-specific manner and during devel-
opment+ Any individual SR protein can complement a
splicing-inactive HeLa S100 extract lacking all the SR
proteins, suggesting functional redundancy for consti-
tutive splicing of at least some pre-mRNAs+ In contrast,
some differences have been detected in the ability of
SR proteins to regulate alternative splicing of different
pre-mRNAs in vitro and in vivo (Zahler et al+, 1993;
Screaton et al+, 1995; Wang & Manley, 1995; for re-
views see Fu, 1995; Manley & Tacke, 1996; Cáceres &
Krainer, 1997)+ Regulation of the expression of many
genes by alternative splicing may be accomplished at
least in part by tissue-specific, developmentally regu-
lated, physiological state-dependent, or virus-induced
variations in the relative levels of one or more SR pro-
teins and the antagonizing hnRNPA/B proteins+ Tissue-
specific variations in the total and relative amounts of
phosphorylated SR proteins, or of mRNAs coding for
SR proteins, have been described (Ayane et al+, 1991;
Fu & Maniatis, 1992; Vellard et al+, 1992; Zahler et al+,
1993; Screaton et al+, 1995)+ Likewise, cell-type spe-
cific variations in hnRNP A/B protein or mRNA levels
have been reported (Faura et al+, 1995; Kamma et al+,
1995; earlier work reviewed in Dreyfuss et al+, 1993)+
However, whether these changes occur in parallel—
which would not be expected to affect alternative
splicing—or whether the relative abundances of these
antagonists vary under natural conditions, was not
known+ To address the mechanisms of alternative splic-
ing regulation by SF2/ASF and hnRNP A1, we raised
monoclonal antibodies specific for SF2/ASF and used
them to determine if the ratio of these proteins is con-
stant or variable in normal and transformed cell lines, in





Human SF2/ASF is a 248-amino acid protein com-
posed of four domains, based on the primary sequence
and on motifs shared with other proteins (Fig+ 1): an
N-terminal RNA-recognition motif (RRM1), a poly-glycine
hinge domain, a central atypical RRM (RRM2), and a
C-terminal arginine/serine-rich (RS) domain (Ge et al+,
1991; Krainer et al+, 1991)+ The RRM is a conserved
80–90-amino acid sequence common to a very large
group of RNA-binding proteins (Kenan et al+, 1991; Bir-
ney et al+, 1993)+ It consists of two short stretches of
predominantly aromatic and hydrophobic residues, the
octamer RNP-1 and the hexamer RNP-2 submotifs,
and of several additional conserved positions that con-
stitute a hydrophobic core+ The domain folds into a
four-stranded antiparallel b-sheet on the side facing
RNA, with two a-helices lying on the opposite side+ The
RS domain is a region of low compositional complexity,
rich in arginine and serine residues, which is charac-
teristic of several metazoan splicing factors and splic-
ing regulators (Birney et al+, 1993)+ The RS domains of
SF2/ASF, and of related members of the SR protein
family, are characterized by arginine–serine periodicity
and by serine phosphorylation at so far undetermined
positions of the domain+
Mice were immunized with purified recombinant pro-
tein consisting of full-length SF2/ASF fused down-
stream of the Escherichia coli malE protein+ Positive
hybridomas were screened by western blotting with the
same protein and with partially purified human SF2/
ASF+ Two clones,mAb96 and mAb103, reacted strongly
and specifically, and were used in further experiments+
A third monoclonal,mAb105,which recognizes the bac-
terial maltose-binding protein portion of the fusion pro-
tein, was also obtained in this screen, and was used as
a negative control in some experiments+
To map the epitopes recognized by mAb96 and
mAb103, we analyzed their reactivity by western blot-
ting with several domain-deletion mutants of SF2/ASF
(Cáceres & Krainer, 1993)+ The intact protein or the
domain fragments were expressed in E. coli with T7
His-tag vectors and affinity purified on nickel-NTA res-
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ins, as described previously+ As summarized in Fig-
ure 1, both monoclonal antibodies,mAb96 and mAb103,
specifically reacted with the N-terminal portion of the
protein comprising RRM1+ We also tested the following
mutants with amino acid substitutions or small dele-
tions within RRM1: (1) PP r RG beginning at residue
54; (2) FAF r DAD beginning at residue 56; (3) EFED
PRDA r TFQNPANV beginning at residue 60; and
(4) RGGPP r RGSGKKRG beginning at residue 51
(Cáceres & Krainer, 1993)+ None of these mutations
affected the reactivity of mAb96 and mAb103, whereas
other anti-SF2/ASF monoclonals were affected by sev-
eral of these mutations and appeared to recognize dis-
continuous epitopes, but were not characterized further+
We conclude that mAb96 and mAb103 recognize either
one of the short regions flanking RRM1 within the first
97 amino acids of SF2/ASF, or a portion of the RRM1
itself, other than loop3, b3, loop4, and the first half of
a2 (Birney et al+, 1993)+ mAb 103 was also used to
study the localization of endogenous SF2/ASF in HeLa
cells by indirect immunofluorescence+ A typical nuclear
speckled pattern and also a diffuse nuclear staining
was observed (Cáceres et al+, 1997)+ Although the two
monoclonals have similar properties and reactivities,
mAb96 gave stronger signals in western blotting,
whereas mAb103 gave clearer staining in immunoflu-
orescence assays (data not shown)+
Phosphorylation state of SF2/ASF
The anti-SF2/ASF monoclonal antibodies (mAbs) were
used to detect the SF2/ASF protein present in HeLa
cell extracts used for splicing+ A band or frequently a
doublet of approximately 33 kDa was detected in nu-
clear extract, as expected (Ge et al+, 1991; Krainer
et al+, 1991); in contrast, the same volume of S100 had
almost no SF2/ASF, as expected from the complemen-
tation assay originally used to purify SF2/ASF (Krainer
et al+, 1990; see below)+ The mobility of SF2/ASF on
SDS-PAGE is affected by its phosphorylation state
(Fig+ 2A), as seen previously with epitope-tagged and
fusion proteins (Roth et al+, 1991; Xiao & Manley, 1997)+
Treatment of SF2/ASF purified from HeLa cells with
bacterial alkaline phosphatase resulted in a marked in-
crease in mobility, such that the dephosphorylated pro-
tein co-migrated with untagged recombinant SF2/ASF
(rSF2/ASF) purified from E. coli (Fig+ 2A, lanes 1–3)+ A
similar increase in mobility upon dephosphorylation was
observed for another SR protein, SC35, as expected
(Fig+ 2A, lanes 4 and 5)+ SR proteins are phosphory-
lated at multiple serine residues within their RS do-
mains, as determined by their reactivity with mAb104,
which recognizes a phosphoepitope (Roth et al+, 1991),
and by studies of in vitro phosphorylation with several
kinases (Gui et al+, 1994b; Colwill et al+, 1996a)+
FIGURE 1. Epitope mapping of anti-SF2/ASF monoclonal antibodies+ The domain structure of SF2/ASF is shown sche-
matically; the main features include two RNA-recognition motifs (RRM1 and RRM2), a poly-glycine hinge (G), and an
arginine/serine-rich domain (RS)+ Full-length and deletion constructs expressed in E. coli (in some cases as fusions with
bacterial proteins or His-tagged) are shown below+ The reactivity of each monoclonal antibody with the different proteins and
fragments, as determined by immunoblotting, is shown on the right+ The subclass of each antibody heavy chain is also
shown+ mAb105 was obtained in the same hybridoma screen and recognizes the maltose-binding protein portion of the
malE-SF2/ASF fusion protein used for immunization+ Four additional recombinant proteins consisting of full-length SF2/ASF
with mutations within RRM1 (residues 54–55, 56 and 58, 60–67, or 51–55) were also tested and showed the same reactivity
as the wild-type protein+
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Because the anti-SF2/ASF mAbs recognize an epi-
tope within the N-terminal RRM, their reactivity with
SF2/ASF should not depend on the phosphorylation
state of the C-terminal RS domain+ Therefore, the anti-
bodies can be used to determine the extent of phos-
phorylation of SF2/ASF in vivo and during the course
of a splicing reaction+ When cells lysates are prepared
under conditions that rapidly denature endogenous
phosphatases, mAb96 reacted only with a single band
with the electrophoretic mobility of maximally phosphor-
ylated protein (see below)+ With gentler lysis conditions
(including SDS lysis at room temperature), or upon pu-
rification of SF2/ASF in the absence of phosphatase
inhibitors, one or more additional bands of greater mo-
bility were detected (data not shown)+ The unphosphor-
ylated protein still migrates slower than predicted from
its calculated mass of 27+7 kDa+ When rSF2/ASF was
used to supplement a HeLa nuclear splicing extract,
the protein became gradually phosphorylated by en-
dogenous kinases, as seen by the gradual decrease in
electrophoretic mobility (Fig+ 2B, compare lanes 3–7 to
lane 1)+ Some phosphorylated rSF2/ASF was already
detected by 5 min of incubation under splicing condi-
tions (Fig+ 2B, lane 3)+ Note that excess rSF2/ASF was
added to the extract in order to distinguish it easily from
endogenous SF2/ASF+ A faint signal corresponding to
highly phosphorylated endogenous SF2/ASF was de-
tected in the exposure shown, both in unincubated nu-
clear extract (Fig+ 2B, lane 2) and after 2 h of incubation
under splicing conditions (Fig+ 2B, lane 8)+
Similar results were obtained when rSF2/ASF was
used to complement a splicing-deficient HeLa S100
extract, which lacks detectable SF2/ASF (Fig+ 2C,
lanes 2 and 8)+ Partially phosphorylated rSF2/ASF was
detected by 15 min of incubation under splicing condi-
tions (Fig+ 2C, lane 4) and only phosphorylated rSF2/
FIGURE 2. Phosphorylation state of SF2/ASF+ A: Phosphatase treatment increases the electrophoretic mobility of SR
proteins+ SF2/ASF and SC35 purified to apparent homogeneity from HeLa cells and baculovirus-infected SF9 cells, re-
spectively, were either mock treated (lanes 1 and 4) or treated with bacterial alkaline phosphatase (BAP) (lanes 2 and 5)+
Proteins were analyzed by 12% SDS-PAGE and stained with Coomassie blue+ Recombinant SF2/ASF (rSF2/ASF) purified
from E. coli was run for comparison (lane 3)+ Bands corresponding to proteins present in the BAP preparation are indicated
on the right+ B: Phosphorylation of recombinant SF2/ASF under splicing conditions in HeLa nuclear extract+ Three pico-
moles of rSF2/ASF were added to 3 mL of nuclear extract, and the mixtures were incubated under splicing conditions in
25-mL reactions+ At the indicated times (lanes 3–7), aliquots were taken and boiled in SDS sample buffer+ Samples were
analyzed by SDS-PAGE, immunoblotting with anti-SF2/ASF mAb96, and enhanced chemiluminescence detection+ Lane 1,
rSF2/ASF, carrier BSA, and buffer only; lane 2, nuclear extract without added rSF2/ASF at time 0; lane 8, same as lane 2,
but incubated at 30 8C for 2 h+ Endogenous SF2/ASF in nuclear extract is present at lower concentrations than the added
protein, and is seen as a faint band in this exposure (lanes 2 and 8)+ C: Phosphorylation of recombinant SF2/ASF under
splicing conditions in HeLa cytosolic S100 extract+ Same as in B, but the reactions in lanes 2–8 contained 7 mL of S100
extract instead of nuclear extract+
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ASF was present after 1 h (Fig+ 2C, lane 6)+ The rapid
kinetics of phosphorylation precluded a simple exper-
iment to determine if phosphorylation of SF2/ASF is
essential for complementation activity+ However, an ap-
parent requirement for SF2/ASF phosphorylation when
nonspecific RNA competitors are included in excess
(Xiao et al+, 1997), or when pre-mRNA is first pre-
incubated with excess SF2/ASF (Cao et al+, 1997), has
recently been reported+The present observations,which
confirm and extend previous studies, show that un-
tagged, unphosphorylated recombinant SF2/ASF is rap-
idly phosphorylated at multiple sites under splicing
conditions, such that its electrophoretic mobility is the
same as that of the endogenous protein+
Immunoprecipitation of spliceosomes
We next attempted to determine if SF2/ASF, which is
required for the assembly of specific pre-spliceosome
complexes (Krainer et al+, 1990; Fu, 1993), is stably
associated with pre-mRNA and/or with the intermedi-
ates and products of splicing+ A splicing reaction with
labeled b-globin pre-mRNA was incubated with mAb96,
and the immune complexes were collected with protein
G-Sepharose+ RNA was extracted from the immuno-
precipitate and the supernatant and analyzed by urea-
PAGE (Fig+ 3)+ The pellet was selectively enriched in
spliced mRNA, although pre-mRNA, exon 1, and the
lariat intermediate and product were also detectable
(Fig+ 3, lane 3)+ A control antibody against a bacterial
protein (mAb105) precipitated only background levels
of all RNA species (Fig+ 3, lane 2), whereas an anti-
hnRNP A1 mAb preferentially precipitated the excised
lariat (Fig+ 3, lane 4), and an anti-hnRNP C1/C2 mAb
bound all RNA species with comparable efficiencies
(Fig+ 3, lane 5)+ We conclude that SF2/ASF associates
stably with b-globin RNA through the splicing reaction
and remains bound to exon sequences after splicing
catalysis, although we cannot rule out the possibility
that SF2/ASF first dissociates from the spliceosome
and then reassociates with the spliced mRNA+ Similar
observations have been made with the SR-related pro-
teins B1C8 and B4A11, which also remain bound to the
mature mRNA after splicing is completed (Blencowe
et al+, 1994, 1995)+
Quantitation of SF2/ASF and hnRNP A1
abundance in HeLa cells
The relative stoichiometries of SF2/ASF and hnRNP
A1 influence alternative splicing in vitro and in co-
transfection experiments (Mayeda & Krainer, 1992;
Cáceres et al+, 1994; Yang et al+, 1994; Wang & Man-
ley, 1995)+ To address the possible splicing regulatory
role of these proteins in vivo, we measured their rela-
tive abundances in HeLa cells by quantitative western
blotting using specific mAbs+ Known amounts of puri-
fied HeLa SF2/ASF or hnRNP A1 proteins and crude
lysates prepared from measured numbers of HeLa cells
were loaded in parallel lanes of an SDS-polyacrylamide
gel+ Following electrophoresis, the proteins were trans-
ferred to nitrocellulose membranes, which were probed
with anti-SF2/ASF mAb96 (Fig+ 4A) or anti-hnRNP A1
mAb9H10 (Piñol-Roma et al+, 1988), respectively
(Fig+ 4B)+ mAb96 is highly specific for SF2/ASF and
does not cross-react with other SR proteins that share
significant sequence homology with SF2/ASF+ It reacts
with a single polypeptide band, or sometimes with a
doublet in HeLa cell lysates or in purified SF2/ASF+ The
lower band is generated by partial dephosphorylation,
FIGURE 3. Immunoprecipitation of splicing reactions+ Standard splic-
ing reactions with 32P-labeled b-globin pre-mRNA were incubated for
90 min and then rocked with monoclonal antibodies immobilized on
protein G-Sepharose+ Immunoprecipitates were washed and the RNAs
extracted and analyzed by urea-PAGE and autoradiography+ Lane 1,
one tenth of the RNA recovered from the supernatant of an immuno-
precipitation with the control mAb105 (against maltose-binding pro-
tein); RNAs recovered from the immunoprecipitates, using the anti-
SF2/ASF mAb96 (lane 3), the anti-hnRNP A1 mAb9H10 (lane 4),
and the anti-hnRNP C1/C2 mAb4F4 (lane 5)+ Structures and mobil-
ities of the precursor, intermediates, and products of the splicing
reaction are indicated on the right side+
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which probably occurs during sample preparation and/or
storage, because this can be largely prevented by the
inclusion of phosphatase inhibitors in the lysis buffer, or
by lysis in hot SDS+ mAb9H10 is also highly specific for
hnRNP A1 and reacts predominantly with a single band
in HeLa cell lysates (Fig+ 4B)+ A less abundant form of
lower mobility corresponds to hnRNP A1B, which is
generated by alternative splicing of hnRNP A1 pre-
mRNA (Buvoli et al+, 1990), but is not seen in HeLa
cells with these short exposures (see below)+
From the data in Figure 4 and from other comparable
titration experiments, we conclude that 2 3 104 HeLa
cells contain the equivalent of 30 ng of SF2/ASF,
whereas 104 HeLa cells contain 37 ng of hnRNP A1+
The molecular weights of SF2/ASF and hnRNP A1 are
;27+7 kDa and ;34+2 kDa, respectively; therefore, we
estimate that a single HeLa cell grown under these
conditions contains 3 3 107 SF2/ASF molecules and
6 3 107 hnRNP A1 molecules+ The protein concentra-
tion of the purified SF2/ASF and hnRNP A1 prepara-
tions was determined using BSA as a standard, which
may result in an overestimate of the actual protein con-
centration+ Because both SF2/ASF and hnRNPA1 have
large domains of low compositional complexity, which
may have nonaverage dye-binding properties, we es-
timate that the above values are probably accurate only
within a factor of 2–3+ However, the value obtained for
hnRNP A1 in HeLa cells is in excellent agreement with
the previously reported value of 7 3 107 molecules per
cell (Kiledjian et al+, 1994)+
The human and mouse SF2/ASF genes have been
shown to encode at least three alternatively spliced
isoforms (Ge et al+, 1991; Tacke et al+, 1992)+ The form
first isolated on the basis of splicing activities is 248
amino acids long, and it was named SF2 or ASF-1 (Ge
et al+, 1991; Krainer et al+, 1991)+ Two other cDNAs
generated by alternative 39 splice-site use or by intron
retention are designated ASF-2 (292 amino acids) and
ASF-3 (201 amino acids)+ When these isoforms are
synthesized in rabbit reticulocyte lysates, their SDS-
PAGE mobilities correspond to approximately 40 kDa
and 20 kDa, respectively (Ge et al+, 1991)+ All three
isoforms share the N-terminal 184 amino acids, and
differ only in the C-terminal regions+ Because mAb96
recognizes the N-terminal RRM, it should detect all the
isoforms if they are expressed as stable proteins in
vivo+ In HeLa cells (Fig+ 4A) and in other lines and
tissues (see below), SF2/ASF was the only isoform
expressed at detectable levels+
Tissue-specific expression of SF2/ASF,
hnRNP A1, and SR proteins
A large number of pre-mRNAs are alternatively spliced
in a tissue-specific manner, giving rise to isoforms with
distinct structures and functions+ The effects of SF2/
ASF and hnRNP A1 on alternative splicing in vitro do
not appear to be strongly substrate specific+ We and
others have shown that altering the ratio of SF2/ASF to
hnRNP A1 causes drastic changes in splice-site utili-
zation of several co-transfected splicing reporters, af-
fecting different patterns of alternative splicing, such as
alternative 59 splice-site selection and exon inclusion/
skipping (Cáceres et al+, 1994; Yang et al+, 1994; Wang
& Manley, 1995)+
It is not known, however, whether SF2/ASF and
hnRNP A1 regulate the in vivo alternative splicing pat-
terns of large groups of genes or perhaps of only a few
specific genes+ Overexpression or disruption of related
proteins in Drosophila, which in some cases lead to
lethality or abnormal development, appear not to result
in generalized alternative splicing defects, at least for
the family members examined (Kraus & Lis, 1994; Ring
& Lis, 1994; Zu et al+, 1996)+ Tissue-specific changes in
the levels or posttranslational modifications of either
protein would be consistent with a regulatory role for
these proteins in vivo+ Systematic studies using mono-
clonal antibodies specific for hnRNP proteins have
shown that the expression of major hnRNP proteins in
FIGURE 4. Abundance of SF2/ASF and hnRNP A1 in HeLa cells+
Purified SF2/ASF or hnRNP A1, and HeLa cell lysates were frac-
tionated by SDS-PAGE and electroblotted onto nitrocellulose
membranes+ Blots were probed with mAb96 (A) or mAb9H10 (B)
and the signals were detected by enhanced chemiluminescence+
A: Lanes 1–4, 40, 20, 10, and 5 ng of purified human SF2/ASF plus
0+1 mg/mL carrier BSA+ Lanes 5–8, total protein from 4 3 104, 2 3
104, 104, and 5 3 103 HeLa cells+ B: Lanes 1–4, 40, 20, 10, and 5 ng
of recombinant hnRNP A1 plus 0+1 mg/mL carrier BSA+ Lanes 5–8,
total protein from 2 3 104, 104, 5 3 103, and 2+5 3 103 HeLa cells+
Mobilities of prestained molecular weight markers are indicated in
kDa on the left side+
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mouse (Kamma et al+, 1995) and in rat (Faura et al+,
1995) tissues varies among different tissues/cell types,
but no studies so far have investigated the ratio of
hnRNP/SR proteins+
For convenience,we analyzed rat tissues, rather than
human ones+ We expected to see cross-reactivity of rat
proteins with mAb96 and mAb9H10, which were raised
against human proteins, because of the exceedingly
high conservation of these proteins+ Rat and human
hnRNP A1 proteins are 100% identical; conservative
substitutions at two positions appear to be allelic, rather
than species specific (Buvoli et al+, 1988)+ The se-
quence of rat SF2/ASF has not been reported, but
human and mouse SF2/ASF proteins are 100% iden-
tical (Birney et al+, 1993)+ Figure 5A shows western
blots of equal amounts of total protein from 10 rat tis-
sues probed with mAb96 (top) and mAb9H10 (middle)+
In the mAb9H10 blot, three bands of different molecu-
lar weights are visible, the lowest of which (34 kDa) is
hnRNP A1+ A1B (38 kDa) is an alternatively spliced
isoform of hnRNP A1, which has weaker alternative
splicing activity (Buvoli et al+, 1990;Mayeda et al+, 1994;
FIGURE 5. Differential expression of SF2/ASF and hnRNP A1 in rat tissues+ A: Total proteins from 10 different rat tissues
were separated by SDS-PAGE and electroblotted onto nitrocellulose membranes+ Top panel: 4 mg of total protein from each
tissue was loaded and the membrane was probed with mAb96+ Middle panel: 6 mg of total protein from each tissue was
loaded and probed with mAb9H10+A1B is an alternatively spliced isoform of hnRNP A1+ Bottom panel: Samples were blotted
and probed under the same conditions as in the middle panel, but omitting the primary antibody+ Asterisk indicates a
nonspecific band that cross-reacts with secondary antibody+ B: Relative amounts of SF2/ASF and hnRNP A1 in rat tissues
were determined by densitometric tracing of the immunoreactive bands on the films shown in the top and middle panels of
A+ The number of molecules of SF2/ASF or hnRNP A1 per microgram of protein in lung tissue (for SF2/ASF) or spleen tissue
(for hnRNP A1) was extrapolated by comparison with known amounts of purified SF2/ASF or hnRNP A1 on the same blots
(data not shown)+ Based on these values, the number of molecules of SF2/ASF and hnRNP A1 per microgram of protein
in each tissue was calculated+ C: Molar ratios of hnRNP A1 to SF2/ASF in each tissue (data from Fig+ 5A) and HeLa cells
(data from Fig+ 4) are shown+
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Yang et al+, 1994)+ Interestingly, the ratio of A1B to A1
proteins varies in different tissues (Fig+ 5A)+ The band
marked by an asterisk is due to cross-reactivity with the
secondary antibody under the detection conditions op-
timized for mAb9H10 (middle and bottom)+ The inten-
sity of each band was quantitated by densitometry+ The
number of SF2/ASF and hnRNP A1 molecules in 1 mg
of total extracted protein for each tissue was deter-
mined by comparison with purified standards, and is
shown in Figure 5B+ The level of SF2/ASF (black bars)
varies widely among tissues, and reached as much as
0+6% of the total extracted protein+ For example, it dif-
fers nearly 20-fold between heart and testis+ In testis,
bands of slightly higher mobility were seen, but we
cannot distinguish whether these represent SF2/ASF
that is underphosphorylated in vivo, or artifactual de-
phosphorylation during sample preparation+ The mo-
bility of SF2/ASF in other rat tissues is the same as in
human 293 cells (Fig+ 5A, lane 1) and HeLa cells (not
shown)+ Therefore, in all of these tissues, SF2/ASF is
highly phosphorylated, and no unphosphorylated pro-
tein was detected+ The levels of hnRNP A1 (gray bars)
also vary widely, with, e+g, an observed 45-fold differ-
ence between heart and spleen+
The observed differences in hnRNP A1 or SF2/ASF
abundances between tissues may underestimate or
overestimate the differences in the nuclear abundances
of these proteins, because the concentration of nuclei
varies considerably among different tissues (Kuehl,
1977), and normalization was on the basis of total pro-
tein (see Materials and Methods)+ However, the ratio of
the two proteins is not affected by the normalization
method+ The calculated molar ratio of hnRNP A1 to
SF2/ASF in each tissue is shown in Figure 5C+ For
example, in pancreas and testis, SF2/ASF is abundant,
whereas hnRNP A1 expression is low, and the hnRNP
A1 to SF2/ASF molar ratio in these tissues is roughly
0+02+ In contrast, SF2/ASF is less abundant and hnRNP
A1 is most abundant in spleen, with a molar ratio of 2+4+
Greater than 100-fold differences in this ratio were ob-
served among tissues+ Because each organ is com-
posed of multiple cell types, even greater differences
between individual cell types may exist+ In most tissues
analyzed, SF2/ASF was present in a molar excess over
hnRNP A1; an excess of hnRNP A1 was seen only in
spleen and in HeLa cells+
In addition to SF2/ASF, the tissue-specific patterns of
expression of other SR proteins were determined by
western blotting with mAb3C5 (Fig+ 6)+ Because this
antibody recognizes a phosphoepitope whose sequence
has not been defined precisely (Turner et al+, 1985), the
relative reactivities of different SR proteins are un-
known+ However, it is apparent from the data that each
tissue expresses a characteristic pattern of SR pro-
teins, of which some are ubiquitous (Fig+ 6)+ This result
is consistent with previous studies of bovine SR pro-
teins using the mAb104 antibody (Zahler et al+, 1993)+
The analysis of SR protein distribution with either
mAb104 or mAb3C5 could give misleading results, if
dephosphorylation occurs during sample preparation,
which would lead to a reduction or loss of immunoreac-
tivity+ Comparison of the signals obtained in the same
samples with mAb96 (Fig+ 6, bottom panel) and the
corresponding SF2/ASF band reacting with mAb3C5
(Fig+ 6, top panel), suggests that little or no dephos-
phorylation of SF2/ASF—and by extension of other SR
proteins—has occurred under the conditions used in
the present study+ One exception was in testes (Fig+ 6,
lane 8), for which SF2/ASF was not detected by
mAb3C5, consistent with the slight increase in the mo-
bility of SF2/ASF (see also Fig+ 5A)+ In general, cell
lysis in boiling SDS or in the presence of phosphatase
inhibitors was essential to preserve 3C5 immunoreac-
tivity and the correct electrophoretic mobilities (data
not shown)+
Effect of transformation on the
hnRNP A1 to SF2/ASF ratio
There are numerous examples of changes in the
patterns of alternative splicing of cellular pre-mRNAs
as a result of oncogenic transformation: a-tropomyosin
(Goodwin et al+, 1991), fibronectin (Borsi et al+, 1987;
Zardi et al+, 1987; Magnuson et al+, 1991; Oyama et al+,
FIGURE 6. Differential expression of SR proteins in rat tissues+ Rat
tissue samples (6 mg each) or 2 3 104 HeLa cells were analyzed by
immunoblotting as in Figure 5, except that the filters were probed
with mAb3C5, which recognizes a phosphoepitope shared by all
known SR proteins+ Bottom panel shows the same samples ana-
lyzed in parallel with mAb96+ Because mAb3C5 but not mAb96 re-
activity is lost upon dephosphorylation, the correspondence of the
SF2/ASF signals in both panels is a measure of the phosphorylation
state of the SR proteins in these samples+
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1993), the CD44 family of glycoproteins (Gunthert
et al+, 1991), and tenascin (Carnemolla et al+, 1992),
among many others+ In addition, increased exon skip-
ping of mRNAs encoding for tumor suppressor genes,
such as the IRF-1 gene (Harada et al+, 1994) and the
WT1 gene (Haber et al+, 1993), has also been associ-
ated with the transformed phenotype, and this could
represent a novel mechanism of tumor suppressor in-
activation+ It is therefore likely that the machinery that
regulates alternative splicing is modified during malig-
nant transformation, leading to the production of par-
ticular protein isoforms that are associated with, and
may be responsible for, the altered phenotype+ As pu-
tative global regulators of alternative splicing, the SR
and hnRNP proteins are excellent candidates for fac-
tors responsible for these extensive alterations in RNA
processing patterns+
We measured the intracellular levels of SF2/ASF and
hnRNP A1 in the rat embryo fibroblast cell line REF52
and in several derivative lines that were transformed by
infection with adenovirus or SV40, or by transfection
with cellular and viral oncogenes+ These cell lines have
been characterized extensively (Garrels & Franza,
1989a, 1989b)+REF52 is a cloned immortal line of post-
crisis Fisher rat embryo cells, and the T24 cell line was
derived from REF52 by transformation with transfected
adenovirus E1A and Ha-ras oncogenes (Franza et al+,
1986)+ Cells were grown as monolayers and samples
were prepared from exponentially growing cells (50–
60% confluent) and from confluent cells (two days after
confluence)+ As shown in Figure 7, the levels of SF2/
ASF changed only very slightly between immortal and
transformed cells (1+2-fold reduction between lanes 1
and 2)+ The levels of hnRNP A1 and A1B both in-
creased fivefold, consistent with previous reports of
increased hnRNP A1 expression in transformed and
rapidly proliferating cells (Celis et al+, 1986; Planck
et al+, 1988; Minoo et al+, 1989; Biamonti et al+, 1993;
Zhang et al+, 1997)+ This increase is comparable to the
fourfold increase observed for PCNA (Fig+ 7, lanes 5
and 6), a common marker for increased expression
upon transformation (Garrels & Franza, 1989b)+ The
overall increase in the hnRNP A1 to SF2/ASF ratio was
calculated from the data in Figure 7 and from other
measurements to be in the range of five- to sixfold+ On
the basis of in vitro experiments with model pre-mRNAs,
a change of this magnitude would be expected to cause
alterations in the alternative splicing patterns for at least
some pre-mRNAs in the transformed T24 line+
SF2/ASF and hnRNP A1 levels
during adenovirus infection
Many adenovirus transcripts are generated by alterna-
tive splicing+ For example, the early region 1A (E1A)
pre-mRNA is spliced into three predominant mRNA spe-
cies termed 13S, 12S, and 9S mRNAs, through the use
of three alternative 59 splice sites and a single 39 splice
site (Berk & Sharp, 1978)+ The 13S and 9S mRNAs are
spliced via the proximal and distal 59 splice site, re-
spectively+ The 13S mRNA predominates during the
early stages of viral infection, whereas the 9S mRNA
predominates during the late stages+ There is evidence
that virus-encoded proteins can directly alter the host
splicing machinery to change the patterns of viral al-
ternative splicing (Svensson & Akusjärvi, 1986; Delsert
et al+, 1989; Nordqvist et al+, 1994)+ The selection of
splice sites in E1A pre-mRNA has been shown to be
modulated by changes in the abundance of hnRNP A1
or SF2/ASF both in vitro (Harper & Manley, 1992; Ma-
yeda & Krainer, 1992) and in transfected cells (Cáceres
et al+, 1994; Yang et al+, 1994; Wang & Manley, 1995)+
A decrease of SF2/ASF and/or an increase of hnRNP
A1 during the early to late transition, at 6–8 h postinfec-
tion, might account for differential E1A splicing in virus-
infected cells+
Seventy to eighty percent confluent HeLa cells were
infected with adenovirus 2 (Ad2) at high multiplicity+
Every 5 h after infection, cells were lysed and analyzed
by western blotting (data not shown)+ Intracellular SF2/
ASF levels increased slightly with time, up to 45 h post-
infection+ However, no significant differences were
observed between mock-infected andAd2-infected cells+
Intracellular hnRNP A1 levels in mock-infected cells
increased gradually during the first 20 h and then lev-
eled off+ In Ad2-infected cells, hnRNP A1 also increased
gradually during the first 20 h postinfection, then de-
creased slightly+ The ratio of hnRNP A1 to SF2/ASF did
not differ significantly during the first 20 h between mock-
infected and Ad2-infected cells+ After 20 h, the ratio
was slightly lower in infected cells+ This is too late to
FIGURE 7. Differential expression of SF2/ASF and hnRNP A1 in
immortal and transformed cell lines+ REF-52 or T24 cells were grown
to confluence and lysates from 5 3 104 cells were analyzed by
western blotting+ Identical pairs of samples were probed with mAb96
(anti-SF2/ASF), mAb9H10 (anti-hnRNP A1), or mAbPC-10 (anti-
PCNA), as indicated+ T24 is a REF-52 derivative transformed with
ras and E1A oncogenes+ These and similar data were quantitated
using NIH Image software+
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account for the E1A early to late switch, and would be
expected to promote the early rather than the late pat-
tern of E1A splicing+ No changes in electrophoretic mo-
bility reflecting the state of phosphorylation were
detected during the infection time course+ Similarly, no
significant changes in the levels or phosphorylation state
of SR proteins were detected by western blotting with
mAb3C5 (data not shown)+
We conclude that a simple model involving changes
in the abundance of SR proteins and/or hnRNP A1
does not account for the regulation of alternative splic-
ing of adenovirus transcripts+ However, recent experi-
ments provided evidence that the transition from early
to late patterns of alternative splicing is modulated by
sequestration of SR proteins by adenoviral RNAs (Gat-
toni et al+, 1991; Himmelspach et al+, 1995)+ This mech-
anism does not involve changes in protein levels that
can be detected by western blotting+
DISCUSSION
We developed monoclonal antibodies specific for the
SF2/ASF splicing factor and used them to study the
abundance of this SR protein in a variety of cell lines
and animal tissues+ In each case, we analyzed the ratio
of SF2/ASF to its antagonist hnRNP A1, because in
vitro splicing studies have suggested that it is the rel-
ative levels of these factors, rather then their absolute
amounts, that determine the selection of alternative
splice sites+ We found that unphosphorylated recom-
binant SF2/ASF undergoes rapid phosphorylation when
added to in vitro splicing reactions+ We also found that
highly or maximally phosphorylated SF2/ASF is the
predominant steady-state form of the protein in vivo,
and no unphosphorylated protein could be detected+
Both SF2/ASF and hnRNP A1 are extremely abun-
dant proteins in the nucleus of exponentially growing
HeLa cells+ The nuclear concentration of these proteins
can be estimated on the basis of: (1) the measured
abundance of 3 3 107 SF2/ASF molecules per cell and
6 3 107 hnRNP A1 molecules per cell (Fig+ 4); (2) the
almost exclusively nuclear localization of both proteins
at steady state (as seen by immunofluorescence and
subcellular fractionation methods); and (3) an esti-
mated diameter of 10 mm for the large, roughly spherical-
shaped nucleus of a HeLa cell grown in suspension,
corresponding to a volume of about 5 3 10213 L+ These
calculations yield an estimated nuclear concentration
of 0+1 mM (;3 mg/mL) for SF2/ASF and 0+2 mM (;7
mg/mL) for hnRNP A1+ These very high concentrations
suggest that most, if not all, pre-mRNAs, including those
lacking high-affinity binding sites, can be bound by mul-
tiple SF2/ASF and hnRNP A1 molecules, at least in
HeLa cells+ This has been suggested previously to be
the case for hnRNP A1 and other core hnRNP proteins
(McAfee et al+, 1997)+
Antagonistic effects between SR proteins and hnRNP
A/B proteins may serve to regulate alternative splicing
events in living cells+ This model is based on experi-
ments showing that transiently increasing the levels of
these proteins in HeLa cells can modulate the alterna-
tive splicing of co-transfected splicing reporters+ For
this model to hold in natural situations, one prediction
is that individual SR and hnRNP A/B proteins should
have unique tissue distributions and abundances+Most
importantly, different ratios of these antagonists should
be present in different in vivo settings+
We found that the abundances of both SF2/ASF and
hnRNP A1 vary widely among rat tissues, and signifi-
cantly, the molar ratio of hnRNPA1 to SF2/ASF showed
variations of greater than 100-fold among certain rat
tissues+ Potentially even greater differences may exist
among the individual cell types that make up these
tissues+ Such changes are expected to have profound
consequences for alternatively spliced transcripts of
genes that are expressed in these tissues, because a
four- to eightfold change of the hnRNP A1 to SF2/ASF
ratio is sufficient to elicit complete switches between
alternative 59 splice sites in vitro (Fu et al+, 1992; Ma-
yeda & Krainer, 1992)+ However, it is not possible to
predict at the present time which and how many spe-
cific cellular transcripts are spliced differentially in re-
sponse to changes in the hnRNP A1 to SF2/ASF ratio+
This, in part, is attributable to the fact that other family
members, and potentially other families of splicing reg-
ulators with similar properties, must also have charac-
teristic tissue-specific abundances+However,we believe
that particular transcripts are alternatively processed
preferentially in response to changes in the levels of
particular sets of hnRNP A/B and SR proteins, with the
necessary specificity arising combinatorially (Screaton
et al+, 1995)+
Unique ratios of SR and hnRNP A/B proteins can be
established in a tissue-specific or developmentally reg-
ulated manner by regulating the expression of their
genes either at a transcriptional or posttranscriptional
level+ Analysis of the promoter regions of several SR
genes has begun recently (reviewed in Cáceres &
Krainer, 1997)+ It has been shown that genes coding for
SR proteins, such as SC35, SRp20, and SRp40, are
upregulated by mitogenic stimuli+ This upregulation may
reflect the requirement for increased RNA splicing as a
result of an overall increase in gene expression during
late G1 phase+ Alternatively, those SR proteins whose
expression is upregulated by mitogens may be in-
volved in specific RNA processing events that may be
required for cell cycle progression+ Analysis of the
hnRNP A1 gene revealed a complex promoter, consis-
tent with the modulation of its expression in response
to different cellular and physiological stimuli (Biamonti
et al+, 1993)+ The intracellular level of hnRNP A1 pro-
tein (and other hnRNP proteins) changes as a function
of the proliferation state in certain cell types, and its
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expression is also upregulated in transformed cell lines+
For instance, hnRNP A2/B1 expression is highly in-
creased in lung cancer cells compared to primary nor-
mal bronchial cells, and this increased expression of
hnRNP A2 may serve as an early marker of lung epi-
thelial transformation and carcinogenesis (Zhou et al+,
1996)+ We observed that hnRNP A1 expression was
significantly increased in REF52 cells that have been
transformed with Ras and E1A (Fig+ 7)+
With respect to posttranscriptional control of SR pro-
tein gene expression, several SR protein genes express
alternatively spliced mRNAs, and the corresponding
cDNAs have been found in libraries prepared from var-
ious tissues (reviewed in Cáceres & Krainer, 1997)+
However, we found no evidence for the expression of
the ASF-2 and ASF-3 isoforms of SF2/ASF as stable
proteins in vivo+ Therefore, it is likely that ASF-2 and
ASF-3 mRNAs are generated as a way to downregu-
late the expression of SF2/ASF, but the presence of
premature nonsense codons in these transcripts may
render them unstable (for review see Maquat, 1995)+
The hnRNP A1 gene also encodes alternatively spliced
isoforms, A1 and A1B (Buvoli et al+, 1990)+ Both iso-
forms were detected as stable proteins in this and in
previous studies, although it has been shown that the
A1B isoform is much less active than the more abun-
dant A1 isoform in vitro and in vivo, at least with the
pre-mRNAs tested (Mayeda et al+, 1994; Yang et al+,
1994)+ The A1B isoform arises from inclusion of an
optional exon, resulting in an internal insertion within
the C-terminal domain (Buvoli et al+, 1990)+ The present
analysis showed that the A1B/A1 protein ratio is tissue
specific (Fig+ 5A)+ The hnRNP A/B proteins A2 and B1
are also isoforms encoded by a single gene; they differ
by the inclusion of a short exon near the 59 end of the
B1 mRNA (Burd et al+, 1989; Biamonti et al+, 1994)+
Both proteins have been detected in vivo, and so far it
appears that both proteins have comparable activities
in alternative splicing (Mayeda et al+, 1994)+
Additional levels of control of SR and hnRNP A/B
protein expression or activity appear to occur at the
posttranslational level+ The SR proteins are phosphor-
ylated in vivo, and, at least under certain conditions,
this posttranslational modification is necessary for con-
stitutive splicing activity in vitro (Cao et al+, 1997; Xiao
et al+, 1997)+ The present study revealed, for the first
time, that unphosphorylated SF2/ASF is not present at
detectable levels in vivo in any of the cell types studied+
Only highly or maximally phosphorylated SF2/ASF was
detected; however, a higher-resolution analysis of the
multiple phosphorylation sites will be required to deter-
mine if one or a few sites of phosphorylation are more
dynamic, and to compare the activities of hypophos-
phorylated and/or hyperphosphorylated forms of the
protein+
hnRNP A1 has also been shown to be phosphory-
lated in vivo (Cobianchi et al+, 1993; Municio et al+,
1995)+ hnRNP proteins are nuclear proteins, but it has
been demonstrated that a subset of them shuttles con-
tinuously between the nucleus and the cytoplasm (re-
viewed in Dreyfuss et al+, 1993)+ We have recently
shown that some, but not all, SR proteins also shuttle
continuously between the nucleus and the cytoplasm
(Cáceres et al+, 1998)+ Nucleo-cytoplasmic trafficking
of these RNA-binding proteins appears to be a regu-
lated process; for example, modulation of hnRNP A1
shuttling is an early cellular response to genotoxic stress
(J+ Lozano, J+F+ Cáceres, A+ Monjas, M+T+ Diaz-Meco,
A+R+ Krainer, & J+ Moscat, in prep+)+ Likewise, over-
expression of the Clk/Sty kinase causes a decrease in
the steady-state levels of SF2/ASF in the nucleus, and
an accumulation of this protein in the cytoplasm
(Cáceres et al+, 1998)+ This effect correlates well with
the effect of Clk/Sty transient overexpression on alter-
native splicing of a co-transfected adenovirus E1A re-
porter gene (Duncan et al+, 1997)+ Therefore, the
regulation of nucleo-cytoplasmic shuttling of SR and
hnRNP proteins may provide an additional mechanism
for modulating the relative abundance of SR and hnRNP
A/B proteins in the nucleus+ It is therefore likely that
signal transduction pathways can affect splicing through
the regulation of phosphorylation and/or nucleo-
cytoplasmic shuttling of splicing factors+ Finally, the ef-
fective levels of SR proteins can be modulated through
sequestration of these proteins by cellular or viral RNAs
with high-affinity binding sites (Himmelspach et al+,
1995)+
In summary, a multiplicity of mechanisms appears to
operate to control the levels and/or activities of specific
SR and hnRNP A/B proteins in response to different
physiological stimuli and in different cell types+ Such
changes provide the flexibility that would be required to
allow these proteins to regulate the alternative splicing
patterns of many different cellular or viral transcripts in
a highly specific manner+
MATERIALS AND METHODS
Proteins
SF2/ASF and hnRNP A1 were purified from HeLa cells as
described previously (Krainer et al+, 1990; Mayeda & Krainer,
1992;Mayeda et al+, 1993)+ Protein concentrations were mea-
sured by the dye-binding method (Biorad), with BSA as a
standard+ MalE-SF2/ASF fusion protein expressed in E. coli
was purified by amylose affinity chromatography (New En-
gland Biolabs)+ Recombinant SF2/ASF and hnRNP A1 wild-
type or mutant proteins were purified from E. coli as described
(Krainer et al+, 1991; Mayeda & Krainer, 1992; Cáceres &
Krainer, 1993; Screaton et al+, 1995)+ Purified SC35 ex-
pressed in baculovirus-infected SF9 cells (Fu & Maniatis,
1992) was a generous gift from X+-D+ Fu and T+ Maniatis+
Antibodies
For preparation of anti-SF2/ASF mAbs, mice were immu-
nized with malE-SF2/ASF fusion protein purified to apparent
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homogeneity+ Standard procedures were used for immuniza-
tion and for generating hybridomas (Harlow & Lane, 1988)+
Antibodies reacting with SF2/ASF were screened in pools by
western blotting with malE-SF2/ASF and with partially puri-
fied HeLa SF2/ASF+ mAb96 is IgG2b, and mAb103 is IgG1+
Anti-hnRNP A1 mAb9H10 and anti-hnRNP C1/C2 mAb4F4
were kindly provided by G+Dreyfuss, and are both IgG+Anti-SR
protein mAb3C5 was a generous gift from B+ Turner+ It rec-
ognizes a family of nuclear phosphoproteins through binding
to a shared phosphoepitope (Turner et al+, 1985)+ This is
apparently the same specificity as that of mAb104 (Roth
et al+, 1991), as also found by others (Bridge et al+, 1995)+
Both antibodies are IgM, but in our hands mAb3C5 is more
sensitive in western blotting+ Anti-PCNA mAbPC-10 (IgG2a)
was obtained from B+ Stillman+ Rabbit anti-DNA binding pro-
tein (DBP) antiserum was a kind gift from E+ Moran+ HRP-
conjugated anti-mouse IgG or IgM secondary antibodies were
purchased from Sigma+
Preparation of cell lysates
HeLa cells were grown in liquid suspension culture in Dul-
becco’s modified Eagle’s medium (DMEM) (GIBCO) supple-
mented with 5% calf serum+ Exponentially growing cells were
collected by centrifugation, suspended in phosphate buffered
saline (PBS) containing 2 mM EDTA, and the cell density was
measured using a hemocytometer+ In the meantime, the cells
were pelleted and immediately resuspended in boiling 23
SDS sample buffer [63 mM Tris-HCl, pH 6+8, 1% (w/v) SDS,
10% (v/v) glycerol, 5% (v/v) b-mercaptoethanol, 0+004% (w/v)
bromophenol blue] and boiled further for 7 min+ REF52 and
T24 cells were grown as monolayers in DMEM supplemented
with 10% fetal bovine serum+ Confluent cells were rinsed in
PBS, resuspended, and counted on a hemocytometer, and
separate aliquots were pelleted and immediately resuspended
in boiling 23 SDS sample buffer and boiled further for 7 min+
Equal numbers of REF52 and T24 cells were used for west-
ern blot analysis+
Adenovirus infection
HeLa cells were grown as monolayers in DMEM with 5%
fetal bovine serum+ Confluent cells (70–80%) were infected
with adenovirus serotype 2 (Ad2) at a multiplicity of infection
of 60–300+ The medium was replaced after 1 h and the
cells were incubated further at 37 8C+ Every 5 h after infec-
tion, the cells were rinsed with PBS, scraped in boiling 23
SDS sample buffer, and boiled further for 7 min+ The effi-
ciency of infection was checked at 24 h postinfection by in-
direct immunofluorescence using anti-DBP antiserum at 1:200
dilution and FITC-conjugated goat anti-rabbit IgG (Sigma) at
1:50 dilution+ Under these conditions, nearly all the cells be-
came infected+
Rat tissue samples
Rapidly frozen rat organs were obtained from Pel-Freez Bi-
ologicals+ Organs were derived from adult (200–300 gram
weight), mixed sex (except for ovaries, testes, and uterus)
Sprague–Dawley rats+ Each batch of a specific organ type
was homogenized with a Polytron (Brinkmann Instruments)
in boiling lysis buffer [50 mM Tris-HCl, pH 6+8, 5% (v/v) glyc-
erol, 0+5% (w/v) SDS, 150 mM NaCl, 2+5% (v/v) b-mercap-
toethanol, 1 mM EDTA]+ Insoluble material was removed by
centrifugation+ An aliquot of each supernatant was diluted
10-fold to reduce the SDS concentration to 0+05%, and its
protein concentration was determined using Coomassie Plus
reagent (Pierce) with BSA as a standard+ The total protein
concentration in each sample was then adjusted to 1 mg/mL
by dilution in lysis buffer+
Western blotting
Samples were separated by SDS-PAGE and electroblotted
onto 0+2-mm nitrocellulose membranes (Schleicher & Schuell)
in 37 mM Tris base, 140 mM glycine in a semi-dry apparatus
(Owl Scientific)+ For probing SF2/ASF, the membrane was
first treated with 0+4% Tween 20/PBS and washed in PBS
prior to blocking+ The membranes were blocked with 10%
nonfat dry milk in TBST (0+1 M Tris-HCl, pH 8, 1+5 M NaCl,
0+5% Tween 20), followed by incubation with anti-SF2/ASF
mAb96 hybridoma supernatant at 1:10 dilution (although much
greater dilutions are also effective) or anti-hnRNP A1
mAb9H10 ascites fluid at 1:1,000 dilution+ After washing five
times with TBST, the membranes were blocked again, incu-
bated with HRP-conjugated anti-mouse IgG at 1:16,000 di-
lution, and washed a further five times+ Immunoreactive protein
bands were detected using the ECL system (Amersham) ac-
cording to the manufacturer’s instructions+ To detect total SR
proteins, the membranes were pre-blocked and blocked as
above, except that 2–5% dry milk was used+ The mAb3C5
hybridoma supernatant and HRP-conjugated anti-mouse IgM
were used at 1:6 and 1:20,000 dilutions, respectively+ The
phosphatase inhibitors sodium fluoride and b-glycerophos-
phate (10 mM each) were added to the blocking solution and
wash buffer+ To detect PCNA, blocking was with 10% dry
milk, the primary IgG2a mAbPC-10 as ascites fluid was di-
luted 1/2,000, and the secondary anti-mouse IgG antibody
conjugate was diluted 1/16,000+
Quantitation of western data
ECL signals were quantitated by densitometry of the films on
a Molecular Dynamics model 110A laser scanner, using Im-
ageQuant version 3+2 software+ For the data in Figure 7, the
films were scanned on a UMAX PS-2400x scanner at 300 dpi
and quantitated with NIH Image version 1+6 software using
the built-in logarithmic calibration+
Dephosphorylation of SR proteins
Dephosphorylation reactions were performed in 30 mL with
1 mg of purified SR protein in 0+3 mM ZnCl2, 0+5 M Tris-HCl,
pH 8+0, and 0+1 units of bacterial alkaline phosphatase (4+8
mg/mL, 31 units/mg; Sigma P4151) for 2 h at 65 8C+ For the
mock reactions, the same volume of enzyme storage buffer
[5 mM Tris-HCl, pH 7+5, 0+5 mM MgCl2, 0+5 mM ZnCl2, 50%
(v/v) glycerol] was added instead of phosphatase+
Immunoprecipitation of spliceosomes
Splicing reactions with radiolabeled b-globin pre-mRNA were
performed in a volume of 250 mL, including 60 mL of HeLa
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nuclear extract+ After incubation for 1+5 h, the reactions were
diluted with 500 mL of IP buffer [20 mM HEPES/Na1, pH 8,
150 mM NaCl, 0+05% (v/v) Triton X100] and incubated with
antibodies pre-immobilized on protein G-Sepharose (10 mL
packed resin)+ The tubes were rocked for 1 h in the cold room
and the bound material was washed four times with IP buffer+
The pellet was suspended in 13 PK buffer (Sambrook et al+,
1989) and the RNA was recovered by phenol extraction and
ethanol precipitation+
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